Few of the pharmacists who pioneered clinical pharmacy practice in the 1960's have continued practicing this form of pharmacy. Many have entered hospital or academic administration, and some have left pharmacy completely. I believe that some pharmacists have chosen to leave clinical positions because they have been frustrated to remain at the resident level, to continue to forever round with housestaff. I feel that the experienced clinician will be willing and eager to continue practicing and teaching as an attending.
Pharmacy should certainly not abandon its peer relationship with the medical housestaff. This is a vital part of patient care and pharmacy practice, and is best left to aspiring undergraduates, Pharm.D./M.S. students, residents, and staff pharmacists who are contemporaries of the medical housestaff in degree of expertise. Supervision and guidance concerning drug therapy would be provided to both the medical housestaff and the pharmacy practitioner by the pharmacy attending. Any number of methods could be developed to complete these "attending" responsibilities: therapeutic walk-rounds, prospective or retrospective auditing of patient records, general therapeutic conferences, clinical pharmacy grand rounds, etc.
To be clinically viable, the attending must have his own practice. As Francke so aptly stated: " . . . a professor of clinical pharmacy soon ceases to be a clinical pharmacist when he is not actually involved in practice." 1 I'm sure we all have witnessed both pharmacy and medical personnel attempting clinical teaching when far removed from patient care themselves. This sort of clinical education is far from ideal.
Subspecialization in clinical pharmacy offers one opportunity for an "attending" pharmacist's practice setting.
The pharmacist could be associated with a specialized department or ward in the hospital (i.e., infectious disease, renal, gastroenterology, etc.) and also have attending responsibilities for a general medical or surgical service which is covered by a pharmacy resident, graduate student, or staff pharmacist. Other opportunities lie in the ambulatory setting; e.g., hospital clinic, community or H.M.O. environment where he could be involved in chronic care, consultations, etc. The attending's practice settings could vary widely, as long as they encompass sufficient direct patient care responsibilities. The skills and experiences obtained in these diverse areas of "private practice" would not only benefit patients, but would also serve as an excellent base for teaching and serving as a role model. Baltimore, Md. 21201 Adverse Drug Reactions-Do We Really Know?
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LIVELY DEBATE CONCERNING THE "adverse drug reaction (ADR) numbers game" has recently appeared in several widely read medical journals. Estimates of yearly deaths due to ADR's have ranged from 2,000 to 140,000, with various intermediate figures also proposed. Each figure comes from individuals with different types of experience and expertise in ADR's, and with different biases and motivations. Following the original estimates which started the controversy, subsequent figures have been presented as accurate accounts of the morbidity and mortality of adverse drug reactions. They are not! Among the limitations which apply to some or all of these studies is lack of information concerning: 1. The adverse effects of drugs on society rather than a specific patient {e.g., overuse of antibiotics promoting development of resistant strains) 2. The ADRs in community hospitals, extended care facilities, and ambulatory settings 3. The ADRs which develop on a long-term basis 4. The ADRs which remain unrecognized or which the physician chooses not to acknowledge 5. The ADRs involving recently introduced drugs 6. The inappropriate use of drugs resulting in lack of efficacy All of the above factors would tend to result in an underestimation of ADRs. Other limitations of these studies would tend to result in overestimation of the public health impact of ADRs, such as inclusion of events as ADRs which are actually due to non-drug causes Drug Intelligence and Clinical Pharmacy VOL 9 JUNE 75 (Nelson Irey terms these "overcalls") and inclusion of ADRs which are a necessary accompaniment of drug therapy of certain diseases. It would be rather fortuitous and quite unlikely that the "overcalls" and "undercalls" would balance resulting in even roughly accurate ADR morbidity and mortality figures for the entire country. There are simply too many unknowns. An additional complicating factor is the inadequacy of the data base on adverse drug reactions. Reserpine was used several decades before the possibility of carcinoma of the breast was raised. The dangers of diethylstilbestrol treatment in pregnant patients were not suspected until vaginal adenocarcinoma was detected in offspring. The long-term adverse effects of oral contraceptives still involve many unknowns, despite use in millions of women. Thus, the current accepted medical view of specific ADRs probably only roughly resembles reality. Using such a data base in epidemiologic studies hardly can be expected to result in "accurate" incidence statistics.
Regardless of whose incidence figures you believe (if any), one simple fact remains: there is little evidence that we have reached the irreducible minimum for ADRs. In fact, a general feeling exists among clinicians experienced in ADRs that we actually have much room for improvement. To imply we are very close to this minimum level is misleading if not irresponsible. If truly definitive studies eventually show that preventable ADRs are infrequent, we can reduce our vigilance and spend more time on other activities with a greater likelihood of benefit for the patient. Until that time, reasonable attention to ADRs by pharmacists and other health professionals is appropriate and in the best interest of the patient. PHILIP D. HANSTEN, Pharm.D.
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Patient Education -A Clinical
Pharmacy Service
THE PROVISION OF COMPLETE CURBENT INFORMATION
concerning diagnosis, treatment, and prognosis in reasonably understood terms by the patient's physician has been cited in the American Hospital Association's "A Patient's Bill of Rights." 1 More recently, physicians have headed interdisciplinary teams of health professionals to coordinate patient education programs in various hospital and clinic settings. Participation in such programs affords the clinical pharmacist an opportunity to provide an additional patient-oriented service.
The provision of patient information serves as the initiation of the education process. Pharmacists have traditionally served as a source of patient information concerning drugs and related health supplies. Although this information is readily supplied to health professionals, few pharmacists communicate such information to the patient. The clinical pharmacist should provide information such as name of the drug entity, indications for use, administration regimen, duration of therapy, possible side effects, and storage requirements to patients during hospitalization, upon discharge, and during clinic visits. A major aspect of patient education implies patient motivation to initiate change in attitude or behavior. Change requires an interdisciplinary evaluation of the patient's total medical needs including an understanding of social, psychological, economic, vocational and cultural characteristics. Patient evaluation results in the preparation of a patient education program consisting of educational objectives submitted by participating health disciplines. The clinical pharmacist, for example, may seek to improve patient adherence to prescribed medication regimens as an educational objective. Provision of drug information to the patient and assurance that medication regimens are simple and compatible with the patient's daily routine may contribute to a change in nonadherent behavior.
Clinical pharmacists, as members of interdisciplinary teams providing patient education, should support research efforts to demonstrate the cost effectiveness of this service. A documented decrease in hospital readmissions would be convincing evidence for budgetary support of patient education as an active patient service. The clinical pharmacist should become acquainted with communication channels available for providing patient education. Written and audio-visual communications can easily be supplemented with verbal communication, thus reducing the professional's time expenditure for patient education. If the clinical pharmacist is available to introduce an education topic, activate an audio-visual device, return after completion of the program to answer questions, and encourage the patient to cooperate and participate in the treatment plan, the objectives of patient education likely will be met.
An inappropriate consultation environment may hamper patient education efforts. Privacy is considered essential for effective communication to result. Utilization of existing space in the patient care area offers the clinical pharmacist the advantages of immediate access to patient records and the presence of other health professionals participating in patient education programs. A private consultation office located within the pharmacy may be effectively utilized if the patient's education program is well defined and close communication is maintained with other health professionals. Although less desirable, consultation booths allow for the dissemination of patient information and represent a significant improvement over the traditional "pharmacy window." Active participation in patient education requires an appreciation of the behavioral sciences and the ability to effectively communicate. Pharmacy educators place little
